Phase 3 Readout

VTVT: Phase 3 Topline: Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-

Name: Phase 3 Topline: Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-
Start: 2027-05-01
End: 2027-05-01

May 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: May 1, 2027
Company: vTv Therapeutics Inc. (VTVT)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 26-Week Double-Blind, Randomized, Placebo-

May 1, 2027

VTVT overview →

Company: vTv Therapeutics Inc. (VTVT)
Indication: Diabetes Mellitus, Type 1